Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADAPTIN BIO, INC.NONE · Entity 9083 | Chief Development Officer | September 08, 2025 | September 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADAPTIN BIO, INC.
Report date September 08, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2035-09-07 | Direct | 109,847 |
Reported balance
After 2025-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-08 · Grant · Acquired 109,847 · Balance 109,847 F1: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2025 Filed Sep 10, 2025 20:59 UTC | ADAPTIN BIO, INC. NONE · Entity 9083 | GrantStock Option (right to buy) · Derivative | 109,847 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001213900-25-086580 · marketforms-70722.xml · derivative · entry 1 Hewitt L Arthur · CIK 0001316983 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,847 Underlying: Common Stock · 109,847 shares Expires 2035-09-07 F1 · derivative.exercise_date: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.